Pheochromocytoma

Pheochromocytoma

Introduction

Pheochromocytoma is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Pheochromocytoma is a rare tumor of the adrenal medulla that arises from chromaffin cells and produces excess catecholamines (epinephrine and norepinephrine). When these tumors occur outside the adrenal gland, they are termed paragangliomas. While classically associated with hypertension and paroxysmal symptoms, emerging research has revealed important connections to neurodegenerative processes and mitochondrial dysfunction. [@serum]

Overview

Pheochromocytoma affects approximately 0.05-0.1% of hypertensive patients, with an annual incidence of 2-8 per million people. Approximately 40% of cases are hereditary, associated with mutations in susceptibility genes including RET (Multiple Endocrine Neoplasia type 2), VHL (Von Hippel-Lindau disease), NF1 (Neurofibromatosis type 1), and SDHx (succinate dehydrogenase complex subunits). These genetic associations highlight the role of mitochondrial dysfunction in tumor pathogenesis. [@allinone]

Pathophysiology

Tumor Biology and Classification

Pheochromocytomas develop from chromaffin cells in the adrenal medulla, which are part of the sympathetic nervous system and responsible for catecholamine synthesis and secretion. The tumors are classified according to their location, hormone production, and malignant potential: [@imibg]

Pheochromocytoma

Introduction

Pheochromocytoma is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Pheochromocytoma is a rare tumor of the adrenal medulla that arises from chromaffin cells and produces excess catecholamines (epinephrine and norepinephrine). When these tumors occur outside the adrenal gland, they are termed paragangliomas. While classically associated with hypertension and paroxysmal symptoms, emerging research has revealed important connections to neurodegenerative processes and mitochondrial dysfunction. [@serum]

Overview

Pheochromocytoma affects approximately 0.05-0.1% of hypertensive patients, with an annual incidence of 2-8 per million people. Approximately 40% of cases are hereditary, associated with mutations in susceptibility genes including RET (Multiple Endocrine Neoplasia type 2), VHL (Von Hippel-Lindau disease), NF1 (Neurofibromatosis type 1), and SDHx (succinate dehydrogenase complex subunits). These genetic associations highlight the role of mitochondrial dysfunction in tumor pathogenesis. [@allinone]

Pathophysiology

Tumor Biology and Classification

Pheochromocytomas develop from chromaffin cells in the adrenal medulla, which are part of the sympathetic nervous system and responsible for catecholamine synthesis and secretion. The tumors are classified according to their location, hormone production, and malignant potential: [@imibg]

• Adrenal pheochromocytoma: Originates in the adrenal medulla, accounts for 80-85% of cases
• Extra-adrenal paraganglioma: Arises from sympathetic ganglia, more likely to be malignant
• Benign vs malignant: Approximately 10-15% are malignant with metastatic potential

Catecholamine Excess and Clinical Manifestations

The hallmark of pheochromocytoma is excessive catecholamine secretion, which produces the classic triad of headaches, sweating, and palpitations, often accompanied by paroxysmal hypertension. The episodic nature of catecholamine release leads to characteristic symptom flares that can be triggered by stress, anesthesia, or certain foods. [@incidental]

Chronic catecholamine excess contributes to: [^6]

• Cardiovascular complications: Hypertensive cardiomyopathy, arrhythmias, myocardial infarction
• Metabolic disturbances: Hyperglycemia, insulin resistance, weight loss
• Neurological symptoms: Headaches, anxiety, panic attacks, tremor

Molecular Mechanisms

The pathophysiology involves dysregulation of several key pathways: [^7]

Genetics and Hereditary Syndromes

Hereditary Associations

Approximately 40% of pheochromocytomas occur in the context of inherited syndromes: [^8]

| Syndrome | Gene | Associated Features | [^9]
|----------|------|---------------------| [^10]
| Multiple Endocrine Neoplasia type 2 | RET | Medullary thyroid cancer, hyperparathyroidism |
| Von Hippel-Lindau disease | VHL | Hemangioblastomas, renal cell carcinoma |
| Neurofibromatosis type 1 | NF1 | Neurofibromas, café-au-lait spots |
| Hereditary paraganglioma syndrome | SDHB, SDHC, SDHD | Extra-adrenal tumors, high malignancy risk |

Mitochondrial Dysfunction

Mutations in SDHx genes encoding succinate dehydrogenase (Complex II) subunits lead to accumulation of succinate, which:

• Inhibits prolyl hydroxylases, stabilizing HIF-1α
• Promotes aerobic glycolysis (Warburg effect)
• Increases reactive oxygen species (ROS) production
• May predispose to neurodegeneration through similar mechanisms

Connection to Neurodegeneration

Shared Pathogenic Mechanisms

Emerging evidence links pheochromocytoma to neurodegenerative processes through several mechanisms:

Parkinson's Disease Connection

Some epidemiological studies suggest an association between pheochromocytoma/paraganglioma and increased [Parkinson's disease](/diseases/parkinsons-disease-disease) risk. Shared mechanisms include:

• Mitochondrial Complex I dysfunction
• [Alpha-synuclein](/proteins/alpha-synuclein) pathology
• [Autophagy](/entities/autophagy)-lysosomal pathway impairment
• [Neuroinflammation](/mechanisms/neuroinflammation)

Therapeutic Implications

Understanding these connections has led to therapeutic strategies that may benefit both conditions:

• Mitochondrial-targeted agents: CoQ10, L-carnitine, MitoQ
• Antioxidant therapy: N-acetylcysteine, vitamin E
• Autophagy enhancers: Rapamycin, trehalose

Diagnosis

Biochemical Testing

The diagnosis rests on biochemical confirmation of catecholamine excess:

• Plasma metanephrines: Sensitivity 97%, specificity 85%
• 24-hour urine catecholamines and metanephrines: Gold standard
• Clonidine suppression test: For equivocal cases

Imaging

Once biochemical diagnosis is confirmed, imaging localizes the tumor:

• MRI: T2-weighted hyperintensity, gadolinium enhancement
• CT: Contrast enhancement, necrosis
• 123I-MIBG scan: Functional imaging for metastatic disease
• 68Ga-DOTATATE PET: Superior sensitivity for SDHB-related tumors

Genetic Testing

Genetic counseling and testing are recommended for all patients with pheochromocytoma given the high hereditary rate:

• Next-generation sequencing panels
• SDHB, SDHC, SDHD, VHL, RET, NF1 analysis
• Family screening when pathogenic variant identified

Treatment

Surgical Management

Surgical resection is the definitive treatment:

• Laparoscopic adrenalectomy: Preferred for tumors <6 cm
• Open surgery: For large or invasive tumors
• Preoperative alpha-blockade: Phenoxybenzamine for 7-14 days
• Beta-blockade: Only after adequate alpha-blockade

Medical Therapy

For inoperable or metastatic disease:

• Alpha-blockers: Phenoxybenzamine, doxazosin, terazosin
• Beta-blockers: Propranolol, atenolol (after alpha-blockade)
• Metyrosine: Tyrosine hydroxylase inhibitor reduces catecholamine synthesis
• Chemotherapy: Cyclophosphamide, vincristine, dacarbazine (Averbuch regimen)
• Radiotherapy: For bone metastases
• 177Lu-DOTATATE: Peptide receptor radionuclide therapy

Follow-up

Long-term monitoring is essential:

• Annual biochemical testing for 10 years
• Imaging for recurrent symptoms
• Genetic counseling for family members
• Blood pressure monitoring

Prognosis

• Benign tumors: Excellent prognosis after surgical resection (5-year survival >95%)
• Malignant disease: 5-year survival 50-70% with aggressive therapy
• Hereditary syndromes: Require lifelong surveillance for recurrence and metastatic spread

See Also

• [Hereditary Paraganglioma](/diseases/hereditary-paraganglioma)
• [Catecholamines](/mechanisms/catecholamines)
• [Dopamine](/dopamine)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Oxidative Stress](/mechanisms/oxidative-stress)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Multiple Endocrine Neoplasia](/diseases/multiple-endocrine-neoplasia)

External Links

• [National Cancer Institute - Pheochromocytoma](https://www.cancer.gov/types/pheochromocytoma)
• [Genetic and Rare Diseases Information Center](https://rarediseases.info.nih.gov/diseases/7359/pheochromocytoma)
• [Pheochromocytoma Registry](https://www.pheochromocytoma.org/)

Background

The study of Pheochromocytoma has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [A time-resolved RNA-sequencing dataset of transcriptional responses in PC12 cells to NGF withdrawal and replenishment.](https://pubmed.ncbi.nlm.nih.gov/41809907/) (2026 Apr) - Data in brief
• [Serum steroid profiling by LC-MS/MS in distinguishing adrenocortical carcinoma from other indeterminate adrenal masses.](https://pubmed.ncbi.nlm.nih.gov/41544796/) (2026 Apr) - The Journal of steroid biochemistry and molecular biology
• [All-in-One Case: Comprehensive Detection of VHL Syndrome With 68 Ga-DOTATATE PET/CT.](https://pubmed.ncbi.nlm.nih.gov/41202074/) (2026 Apr 1) - Clinical nuclear medicine
• [131 I-MIBG and 18 F-FDG PET/CT in a Case of Synchronous Right Pheochromocytoma and Undifferentiated Uterine Carcinoma.](https://pubmed.ncbi.nlm.nih.gov/40938186/) (2026 Apr 1) - Clinical nuclear medicine
• [Incidental Discovery of Synchronous Ileal Neuroendocrine Tumors at Fluorodopa PET/CT in a Patient With Bilateral Pheochromocytoma.](https://pubmed.ncbi.nlm.nih.gov/40658992/) (2026 Apr 1) - Clinical nuclear medicine

References